JAZZ vs LYRA · P/E 1988, rev $2.28B vs rev $1.5M
Jazz Pharmaceuticals PLC (JAZZ) versus Lyra Therapeutics Inc (LYRA) — a side-by-side from cached financials, not a winner call.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
Lyra Therapeutics Inc (LYRA) is a biotechnology company listed on US.
Latest reported JAZZ revenue for 2026-06-30 was $2.28B. Net income was $485.9M. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Latest reported LYRA revenue for 2024-12-31 was $1.5M. Net income was -$93.4M. Revenue was down 1.5% from 2023-12-31 to 2024-12-31. LYRA currently screens at market cap $14.4M.
JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1. LYRA currently screens at market cap $14.4M.
Not investment advice. Open the JAZZ and LYRA stock pages for the full models.
Not investment advice.